The Parexel Podcast | Episode 13: The New Pragmatism: Clinical Trials, Investment and Regulations Post-COVID-19

Once the COVID-19 pandemic passes or is contained, the world will look and work very differently. The biopharmaceutical industry is no exception. In this podcast, Peyton Howell, Chief Operating and Growth Officer, talks with Paul Bridges, Head of Consulting, and Sheela Hegde, a Partner with Parexel’s Health Advances subsidiary, about the regulatory, investing and clinical development changes that are most likely here to stay – The New Pragmatism. After listening, you can read more about Paul and Sheela’s perspective in this article: https://regulatory-access.parexel.com/parexels-covid-19-expert-content/covid-19-and-the-new-pragmatism

Return to Insights Center

Related Insights

Related Insights

Webinar

Accelerating vaccine development through operational excellence

May 16, 2024

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Podcast

Enabling Successful Sites, Episode 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training

Jun 28, 2024

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Show more